MDGL Earnings Date: Nov 3, 2026 (Estimated) — Madrigal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is MDGL's next earnings date?
Madrigal Pharmaceuticals, Inc. (MDGL) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.86 on revenue of $404.2M.
How did MDGL do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Madrigal Pharmaceuticals, Inc. posted EPS of -$1.99 versus the -$2.32 estimate, a beat of 14.2%. Revenue was $364.3M against a $349.6M estimate. The stock's 1-day post-earnings move was -9.8%.
How much does MDGL stock move after earnings?
MDGL beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.5% (up or down) in the day after earnings.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -2.32 | -1.99 | +14.22% | $364.3M | ✅ Beat | -9.83% | -5.99% | -0.58% |
| 2026-05-06 | Q1 2026 | -4.04 | -3.25 | +19.55% | $311.3M | ✅ Beat | +7.42% | +1.55% | -1.92% |
| 2026-02-19 | Q4 2025 | -0.52 | -2.57 | -394.23% | $321.1M | ❌ Miss | -11.11% | -11.49% | -7.58% |
| 2025-11-04 | Q3 2025 | -1.99 | -5.08 | -155.28% | $287.3M | ❌ Miss | +7.83% | +20.26% | +40.63% |
| 2025-08-05 | Q2 2025 | -3.52 | -1.90 | +46.02% | $212.8M | ✅ Beat | +8.59% | +11.98% | +39.46% |
| 2025-02-26 | Q4 2024 | -4.12 | -2.71 | +34.22% | $103.3M | ✅ Beat | +14.99% | +3.82% | +7.86% |
| 2024-10-31 | Q3 2024 | -6.91 | -4.92 | +28.80% | $62.2M | ✅ Beat | +20.10% | +56.63% | +51.99% |
| 2024-08-07 | Q2 2024 | -7.54 | -7.10 | +5.84% | $14.6M | ✅ Beat | -12.18% | -8.60% | -7.71% |
Showing last 8 quarters.